Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: A novel link between interferon-α and atherosclerosis in lupus

Arthritis and Rheumatism

Volumn 63, Issue 2, 2011, Pages 492-502

  Li, Jia ^a   Fu, Qiong ^a   Cui, Huijuan ^b   Qu, Bo ^b   Pan, Wen ^b   Shen, Nan ^a   Bao, Chunde ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALPHA INTERFERON; CD36 ANTIGEN; CD68 ANTIGEN; LIPID; LUCIFERASE; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCAVENGER RECEPTOR; STAT1 PROTEIN;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FOAM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID TRANSPORT; MACROPHAGE; MONOCYTE; OIL RED O STAINING; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RISK FACTOR; SIGNAL TRANSDUCTION; STAINING; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ATHEROSCLEROSIS; CELL LINE, TUMOR; FEMALE; FOAM CELLS; GENE EXPRESSION; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; LIPID METABOLISM; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS A; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 79551678138     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30165     Document Type: Article

References (50)

1. Thompson T, Sutton-Tyrrell K, Wildman RP, Kao A, Fitzgerald SG, Shook B, et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008; 58: 835-42.
2. Salmon JE, Roman MJ,. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008; 121 (10 Suppl 1): S3-8.
3. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406.
4. Bessant R, Duncan R, Ambler G, Swanton J, Isenberg DA, Gordon C, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Rheum 2006; 55: 892-9. (Pubitemid 44917462)
5. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-7.
6. Hahn BH,. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003; 349: 2379-80.
7. Roman MJ, Salmon JE,. Cardiovascular manifestations of rheumatologic diseases. Circulation 2007; 116: 2346-55.
8. Agarwal S, Elliott JR, Manzi S,. Atherosclerosis risk factors in systemic lupus erythematosus. Curr Rheumatol Rep 2009; 11: 241-7.
9. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Pratt JE, Tracy RP, Kuller LH, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 151-9.
10. McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2428-37.
11. McMahon M, Hahn BH,. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 2007; 19: 633-9.
12. Hahn BH, Grossman J, Chen W, McMahon M,. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007; 28: 69-75.
13. Pascual V, Farkas L, Banchereau J,. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006; 18: 676-82. (Pubitemid 44635182)
14. Banchereau J, Pascual V,. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25: 383-92.
15. Baechler EC, Gregersen PK, Behrens TW,. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004; 16: 801-7.
16. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-5.
17. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr., Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005; 64: 1692-7.
18. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3958-67.
19. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777-88.
20. Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L,. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 2009; 30: 455-64.
21. Nacionales DC, Kelly-Scumpia KM, Lee PY, Weinstein JS, Lyons R, Sobel E, et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 2007; 56: 3770-83.
22. Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 3759-69.
23. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, et al. Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007; 110: 2907-15.
24. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM,. Synergistic proinflammatory effects of the antiviral cytokine interferon-α and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation 2007; 116: 2043-52.
25. Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM,. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-α. Circulation 2006; 114: 2482-9.
26. Levy Z, Rachmani R, Trestman S, Dvir A, Shaish A, Ravid M, et al. Low-dose interferon-α accelerates atherosclerosis in an LDL receptor-deficient mouse model. Eur J Intern Med 2003; 14: 479-83.
27. Hartvigsen K, Chou MY, Hansen LF, Shaw PX, Tsimikas S, Binder CJ, et al. The role of innate immunity in atherogenesis. J Lipid Res 2009; 50 Suppl: S388-93.
28. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
29. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
30. Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv LB,. IFN-α priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 2004; 172: 6476-81.
31. Osto E, Kouroedov A, Mocharla P, Akhmedov A, Besler C, Rohrer L, et al. Inhibition of protein kinase C β prevents foam cell formation by reducing scavenger receptor A expression in human macrophages. Circulation 2008; 118: 2174-82.
32. Moore KJ, Freeman MW,. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006; 26: 1702-11.
33. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002; 277: 49982-8.
34. Matsumoto A, Naito M, Itakura H, Ikemoto S, Asaoka H, Hayakawa I, et al. Human macrophage scavenger receptors: primary structure, expression, and localization in atherosclerotic lesions. Proc Natl Acad Sci U S A 1990; 87: 9133-7.
35. Platanias LC,. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375-86.
36. Moulton KS, Semple K, Wu H, Glass CK,. Cell-specific expression of the macrophage scavenger receptor gene is dependent on PU.1 and a composite AP-1/ets motif. Mol Cell Biol 1994; 14: 4408-18.
37. Li K, Yao W, Zheng X, Liao K,. Berberine promotes the development of atherosclerosis and foam cell formation by inducing scavenger receptor A expression in macrophage. Cell Res 2009; 19: 1006-17.
38. Xu WY, Wang L, Wang HM, Wang YQ, Liang YF, Zhao TT, et al. TLR2 and TLR4 agonists synergistically up-regulate SR-A in RAW264.7 through p38. Mol Immunol 2007; 44: 2315-23.
39. Zhuang H, Narain S, Sobel E, Lee PY, Nacionales DC, Kelly KM, et al. Association of anti-nucleoprotein autoantibodies with upregulation of type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin Immunol 2005; 117: 238-50.
40. De Winther MP, van Dijk KW, Havekes LM, Hofker MH,. Macrophage scavenger receptor class A: a multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 290-7.
41. Galkina E, Ley K,. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 2009; 27: 165-97.
42. Zhao W, Somers EC, McCune WJ, Kaplan MJ,. Type I interferon gene signatures are associated with vascular risk and atherosclerosis in systemic lupus erythematosus [abstract]. Arthritis Rheum 2009; 60 Suppl 10: 582.
43. Crow MK,. Developments in the clinical understanding of lupus. Arthritis Res Ther 2009; 11: 245.
44. Gerrity RG, Naito HK, Richardson M, Schwartz CJ,. Dietary induced atherogenesis in swine: morphology of the intima in prelesion stages Am J Pathol 1979; 95: 775-92.
45. Linton MF, Fazio S,. Class A scavenger receptors, macrophages, and atherosclerosis. Curr Opin Lipidol 2001; 12: 489-95.
46. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997; 386: 292-6.
47. Durst R, Neumark Y, Meiner V, Friedlander Y, Sharon N, Polak A, et al. Increased risk for atherosclerosis of various macrophage scavenger receptor 1 alleles. Genet Test Mol Biomarkers 2009; 13: 583-7.
48. Grewal T, Priceputu E, Davignon J, Bernier L,. Identification of a gamma-interferon-responsive element in the promoter of the human macrophage scavenger receptor A gene. Arterioscler Thromb Vasc Biol 2001; 21: 825-31.
49. Agrawal S, Febbraio M, Podrez E, Cathcart MK, Stark GR, Chisolm GM,. Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development. Circulation 2007; 115: 2939-47.
50. Nakayama M, Kudoh T, Kaikita K, Yoshimura M, Oshima S, Miyamoto Y, et al. Class A macrophage scavenger receptor gene expression levels in peripheral blood mononuclear cells specifically increase in patients with acute coronary syndrome. Atherosclerosis 2008; 198: 426-33.